Sanofi (EPA:SAN)
104.12
+0.54 (0.52%)
Feb 21, 2025, 5:38 PM CET
Sanofi Employees
Sanofi had 82,878 employees as of December 31, 2024. The number of employees decreased by 3,210 or -3.73% compared to the previous year.
Employees
82,878
Change (1Y)
-3,210
Growth (1Y)
-3.73%
Revenue / Employee
€534,352
Profits / Employee
€67,087
Market Cap
130.52B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 82,878 | -3,210 | -3.73% |
Dec 31, 2023 | 86,088 | -5,485 | -5.99% |
Dec 31, 2022 | 91,573 | -3,869 | -4.05% |
Dec 31, 2021 | 95,442 | -3,970 | -3.99% |
Dec 31, 2020 | 99,412 | -997 | -0.99% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
Company Name | Employees |
---|---|
EssilorLuxottica Société anonyme | 200,000 |
Sartorius Stedim Biotech | 10,662 |
bioMérieux | 13,982 |
Eurofins Scientific SE | 63,000 |
Ipsen | 5,325 |
Virbac | 5,459 |
emeis Société anonyme | 77,954 |
Ramsay Générale de Santé | 34,218 |
Sanofi News
- 9 hours ago - Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn's disease - GlobeNewsWire
- 1 day ago - Stocks to watch today on 21 Feb: Cipla, Senores, Narayana Hrudayalaya, Sanofi in pharmaceuticals and healthcare sector - Business Upturn
- 1 day ago - Chronic Spontaneous Urticaria Market to Register Incremental Growth During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight - Benzinga
- 3 days ago - Sanofi: OpenAI's Research Agents Could Lead To Explosive Growth - Seeking Alpha
- 3 days ago - Sanofi to sell 50% stake in consumer health unit to CD&R - Seeking Alpha
- 3 days ago - Press Release: Sanofi and CD&R sign Opella share purchase agreement - GlobeNewsWire
- 3 days ago - Regeneron, Sanofi asthma therapy Dupixent under FDA review for rare skin condition - Seeking Alpha
- 7 days ago - Sanofi gets FDA approval for NovoLog insulin biosimilar - Seeking Alpha